September 24, 2025
IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2025
Aggregated presentation by day and by marketStatement of transactions in own shares from September 15th to September 19th 2025 Name of…
Pharmaceuticals, Biotechnology and Life Sciences
Aggregated presentation by day and by marketStatement of transactions in own shares from September 15th to September 19th 2025 Name of…
PALO ALTO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) — Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) (OTC: SMNR, SMNRW) ,…
BioLegacy’s New Vancouver Hub Drives Innovation in Opioid Crisis Solutions with Unmatched Manufacturing and Research CapabilitiesVANCOUVER, British Columbia, Sept. 23,…
MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces…
KEY LARGO, Fla., Sept. 23, 2025 (GLOBE NEWSWIRE) — Remedy’s Nutrition®, a trusted natural dietary supplement company since 1972 and…
LOS ANGELES, Sept. 23, 2025 (GLOBE NEWSWIRE) — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for…
PALO ALTO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative…
DURHAM, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO),…
CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the…
Cash and cash equivalents totaled €107.5 million as of June 30, 2025, excluding the €26.5 million milestone invoiced in May…